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Abstract
The evidence base available to trialists to support trial process decisions—e.g. how best to recruit and retain
participants, how to collect data or how to share the results with participants—is thin. One way to fill gaps in
evidence is to run Studies Within A Trial, or SWATs. These are self-contained research studies embedded within a
host trial that aim to evaluate or explore alternative ways of delivering or organising a particular trial process.
SWATs are increasingly being supported by funders and considered by trialists, especially in the UK and Ireland. At
some point, increasing SWAT evidence will lead funders and trialists to ask: given the current body of evidence for
a SWAT, do we need a further evaluation in another host trial? A framework for answering such a question is
needed to avoid SWATs themselves contributing to research waste.
This paper presents criteria on when enough evidence is available for SWATs that use randomised allocation to
compare different interventions.
Introduction
The evidence available to inform many routine process
decisions in randomised trials is thin or weak. This in-
cludes the evidence on how best to recruit participants
[1], retain them [2], collect their data [3] or include them
in decisions about the trial [4]. While evidence gaps in,
say, the clinical management of diabetes might be ex-
pected to lead to a sustained and substantial research ef-
fort to fill them, similar effort has not materialised for
trial methods research. Recruitment remains a major
concern [5, 6] despite more than 25,000 new trials open-
ing every year and needing to recruit participants [7].
Once recruited, there is also little evidence available to
inform decisions about how to encourage trial partici-
pants to remain in the trial and, for example, to attend
face-to-face measurement visits, which are a vital part of
most trials [2]. Further, there is almost no evidence base
to inform trial management decisions, including how to
select sites, whether visiting them in person is worth it,
or how to train staff [8].
The lack of trial process evidence contributes to re-
search waste—for example, through poor recruitment,
retention and data quality—and has been a feature of
medical research for decades [9], with some suggesting
that up to 85% of medical research spending is wasted
[10]. However, much of the waste is avoidable [11] and
research funders recognise the need to avoid it [12].
Trial Forge (http://www.trialforge.org) is an initiative
that aims to improve the efficiency of trials, particularly by
filling gaps in trial process evidence [13]. One way of im-
proving the evidence base for trial process decisions is to
do a Study Within A Trial (SWAT) [14], which is a ‘...self-
contained research study that has been embedded within
a host trial with the aim of evaluating or exploring alterna-
tive ways of delivering or organising a particular trial
process’ [15]. For example, a SWAT could evaluate a new
way of presenting information to potential participants as
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a way of improving trial retention, perhaps by being
clearer about what taking part in the trial entails. Half of
potential participants could be randomised to receive the
new information while the other half receive the standard
information. The effect of the new information on trial re-
tention could be measured at the end of the trial or pos-
sibly part-way through if the trial has a long duration.
Other interventions that could be evaluated in a SWAT
include remote site training compared to face-to-face
training, sending participants thank-you letters after at-
tending trial visits and sending birthday cards to children
in paediatric trials to improve retention. Any improve-
ments that will arise from using an alternative approach
for a particular process are likely to be modest but the
combined effect of small improvements across many pro-
cesses may well be substantial.
There is a growing repository of protocols for SWATs
(http://bit.ly/20ZqazA) and Madurasinghe and col-
leagues have developed a reporting standard for recruit-
ment SWATs, which are a priority for trial methodology
research [16–18]. Moreover, major funders are taking
the need for SWATs seriously as a vehicle for more effi-
cient use of public resources. For example, the UK’s Na-
tional Institute for Health Research Health Technology
Assessment program (NIHR HTA) now highlights
SWAT funding in all its trial funding calls and was the
topic of a recent ‘HTA Director’s Message’ (https://
www.youtube.com/watch?v=PoIE6xxK-pA). The Health
Research Board Trial Methodology Research Network
(HRB-TMRN) in Ireland also funds SWATs [19] and the
Health Research Board encourages investigators to in-
clude a SWAT when applying for funding for both feasi-
bility and definitive trial funding [20].
An important question to ask when thinking about
undertaking SWATs is how to prioritise interventions
for their first evaluation in a SWAT. A good example of
a prioritisation process for unanswered questions for
trial recruitment is the PRioRiTY project [18] (https://
priorityresearch.ie). PRioRiTY 2 does the same for trial
retention [21].
The scope of the work described here is what happens
after the first evaluation. When evidence is available for
an intervention or some aspect of the trial process, how
should one decide if further evaluation is needed in an-
other SWAT? Deciding whether a particular interven-
tion needs further evaluation will always be a judgement.
The objective of this Trial Forge guidance is to provide a
framework for making this an informed judgement
based on explicit criteria that most trialists and method-
ologists can agree with. We take a pragmatic stance
about evidence generation: trial teams need enough evi-
dence to know whether something is worth doing, no
more and no less. The aim is to avoid wasting research
effort evaluating interventions for which there is already
good enough evidence for decision-making, allowing at-
tention to re-focus on those interventions where import-
ant uncertainty still exists. This paper presents criteria
for how to do this for SWATs that use randomised allo-
cation to compare different interventions.
The guidance is written from the perspective of
whether a single research team should do a further sin-
gle evaluation of a SWAT in a single host trial as this is
currently the most likely approach to doing a SWAT.
Although we take a single SWAT perspective in this
guidance, we expect it to apply equally well to SWATs
done as part of a coordinated package of evaluations.
Proposed criteria for making informed
judgements about further SWAT evaluation
The main users of SWAT results will be members of
trial teams. Funders of SWATs and trials are also likely
to be interested. To make informed judgements, these
users need to know what the accumulating evidence is
for the effect of the SWAT on one or more relevant trial
process outcomes (e.g. recruitment, retention), as well as
the certainty for that evidence. They will want to know
whether the evidence comes from evaluations done in
contexts similar to their own. Finally, they will want to
know how finely balanced the advantages and disadvan-
tages of using the SWAT are, both for trial participants
and the host trial.
Given the above, the five criteria we propose for decid-
ing whether a further SWAT evaluation is needed are
listed in Table 1. The aim of applying these criteria is to
ensure that the need for a new evaluation is considered
explicitly in light of what is already known about the
intervention. Generally speaking, the more criteria that
are met, the more likely we are to conclude that a new
evaluation in a SWAT is appropriate. Conversely, if none
of the criteria are met it is unlikely that a new evaluation
would be appropriate.
To illustrate the use of these criteria, we have applied
them to examples from the Cochrane Review on strat-
egies to improve trial recruitment [1] and the Cochrane
Review on strategies to improve trial retention [2].
Example 1: telephoning non-responders to trial
invitations
Background
Only two interventions in the 2018 version of the
Cochrane Review for trial recruitment [1] have both high
certainty for the evidence and a potential for widespread
applicability. One of these is telephoning people who do
not respond to postal invitations to take part in a trial,
which is used in this example. (The other relates to opti-
mising the patient information leaflet.) The Cochrane
Review notes that the rating of high certainty is only for
trials with low underlying recruitment of < 10% of
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eligible participants. If the evidence is to be applied to
trials with higher underlying recruitment, the review au-
thors suggested that the GRADE rating be reduced from
high to moderate because of indirectness.
A trial team that includes people with lived experience
of the illness or condition targeted is likely to consider
information about the following essential when deciding
whether a further evaluation of telephone reminders
should form part of their recruitment strategy:
i. effect on recruitment
ii. cost
iii. participant irritation at receiving the telephone call
Applying the five criteria
Table 2 summarises the results of the two telephone re-
minder trials and the overall estimate of effect.
Applying the criteria in Table 1:
1. GRADE. Data are available for recruitment only
(two trials, n = 1450). The GRADE certainty in the
evidence for the two trials in the review is high but
is considered moderate for trials that do not have
low (< 10%) underlying recruitment. Criterion
partially met (the GRADE certainty in the evidence
for all essential outcomes is lower than ‘high’).
2. Cumulative evidence. Data are available for
recruitment only. There are only two trials and it
seems too early to claim the cumulative meta-
analysis has converged. Criterion met (the effect
estimate for each essential outcome has not
converged).
3. Context. The PICOT for the available evidence is:
 P – One study was done in Norway in 2002–
2003 and involved people aged 16–66 years who
were sick-listed for > 7 weeks due to non-severe
psychological problems or musculoskeletal pain.
The second study was done in Canada in 2010
Table 1 Should we do a further evaluation of the intervention in a SWAT?
The five proposed criteria for deciding whether the intervention needs another evaluation in a SWAT. The more criteria that are met, the more likely
we are to conclude that further evaluation in a SWAT is appropriate.
1. GRADE: the GRADE [22] certainty in the evidence for all key outcomes is lower than ‘high’.a
2. Cumulated evidence: the cumulative meta-analysis shows that the effect estimate for each outcome essential to make an informed decision has
not converged.b,c
3. Context: the range of host trial contexts evaluated to date does not translate easily to the context of the proposed SWAT.d For the proposed
SWAT consider PICOT [23]:
• P – is the population in the host trial so different from those already included that the current evidence does not provide sufficient certainty?
• I – are the health interventions in the host trial so different from those already included that the current evidence does not provide sufficient
certainty?
• C – is the comparator in the host trial so different from those already included that the current evidence does not provide sufficient certainty?
• O – is the SWAT outcome(s) so different to those used in the existing evaluations that that the current evidence does not provide sufficient
certainty?
• T – in the time since the existing evaluations were done, have regulatory, technological or societal changes made those evaluations less relevant?
4. Balance – participants: the balance of benefit and disadvantage to participants in the host trial and/or the SWAT is not clear.e
5. Balance – host trial: the balance of benefit and disadvantage to the new host trial is not clear.f
Notes
a A GRADE assessment of ‘high’ means that we are confident that the true effect lies close to the estimate of effect coming from the cumulative meta-analysis
[24]. In Cochrane’s deliberations as to when to close a Cochrane Review (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000107/full), the
collaboration chose not to require ‘high’ GRADE certainty in the evidence because it was felt that this may not always be achievable. Although we recognise the
pragmatic nature of this, we recommend ‘high’ in our criteria because SWATs are usually simple studies for which it should be possible to generate high certainty
evidence. We will, however, keep this criterion under review to consider whether it needs relaxing.
b This is a judgement that depends on the behaviour of the effect estimates and on whether the confidence intervals include the threshold for an important
benefit (or disadvantage). For example, if there is drift in the effect estimates of a meta-analyses but the confidence intervals around the estimates are
consistently above what you think is an important benefit (or below a relevant disadvantage) then the cumulative meta-analysis can be judged to have
converged despite movement in the effect estimates. For more on GRADE see http://www.gradeworkinggroup.org.
c This is a judgement that depends on the behaviour of the effect estimates and on whether the confidence intervals include the threshold for an important
benefit (or disadvantage). For example, if there is drift in the effect estimates of a meta-analyses but the confidence intervals around the estimates are
consistently above what you think is an important benefit (or below a relevant disadvantage) then the cumulative meta-analysis can be judged to have
converged despite movement in the effect estimates. For more on GRADE see http://www.gradeworkinggroup.org.
d This is to provide reassurance about the applicability of the result to different types of trials. Care is needed to avoid a default position of insisting on an
evaluation in every conceivable context. In other words, is there any reason to believe that the intervention would not work in your context given the contexts
already studied? It is possible that evidence from SWATs will eventually splinter off to focus specifically on certain contexts but, for now, we suggest pooling
evaluations of the same intervention because there are so few SWAT evaluations of any intervention and this pooling will provide a basic foundation on which
to build.
e Where there may be no conceivable benefit or disadvantage for participants, they should be considered as balanced.
f A benefit might be that the host trial recruits faster, or its data quality is improved. Examples of disadvantages might be that there are added costs to the host
trial, or that a new task is introduced into the workload of trial managers.
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and involved people aged 50–70 years from
family practice lists who were eligible for
colorectal cancer screening.
 I – The host trial intervention in the Norwegian
study was solution-focused sessions led by
psychologists that were one-on-one or in groups
and aimed to help people get back to work. The
host trial interventions in the Canadian study
were one of virtual colonoscopy, optical
colonoscopy or faecal occult blood testing.
 C – The host trial comparator in the Norwegian
study was usual care: written information from
the social security office. The Canadian host trial
was doing a head-to-head evaluation of three
screening methods, so the three interventions
mentioned above were also the comparators.
 O – Both studies measured recruitment to the
host trial. Both host trials had low underlying
recruitment.
 T – Mobile telephones have replaced home-
based phones for many people and neither study
explicitly includes mobile telephones.
Considering the above, leads to Criterion partially
met (a new evaluation is likely to contain several ele-
ments in the PICOT that are importantly different to
those in the two existing evaluations).
1. Balance – participants. There is little or no direct
benefit to participants, although some may like
being reminded about the trial. One potential
disadvantage is that some participants may be
irritated by the reminder call but what proportion
would be irritated is unclear. Criterion met (the
balance of benefit and disadvantage to participants
in the new host trial and/or SWAT is not clear)
2. Balance – host trial. The benefit to the host trial is
a small increase in recruitment if underlying
recruitment is low but it is unclear what the benefit
would be if underlying recruitment was higher.
There is a potential disadvantage to the host trial of
over-burdening trial staff with making the reminder
telephone calls but the size of this disadvantage is
unclear. Criterion met (the balance of benefit and
disadvantage to those running the host trial is not
clear)
Considering the responses across all five criteria leads
us to conclude that further evaluation of telephone re-
minders is needed and especially where underlying re-
cruitment is anticipated to be > 10%. The views of
people with lived experience of the conditions targeted
by host trials on receiving telephone reminder calls
should be sought in future evaluations. More informa-
tion on cost and the potential disadvantages for the host
trial would also be welcome, as would evaluations that
used mobile telephones.
Figure 1 shows how the evidence with regard to tele-
phone reminders for recruitment might be shown on the
Trial Forge website. The cumulative meta-analysis in
this summary shows four decision thresholds (absolute
difference of 0%, 5%, 10% and 15%) that trialists can use
Table 2 The cumulative effect estimates for the two telephone reminders compared to no reminder studies included in the
updated Cochrane recruitment interventions review [1]
Total number of
participants
Intervention (n
recruited/N
invited)
Control (n
recruited/N
invited)
Baseline
(control)
recruitment rate
Effect
estimate
(95% CI)
Nystuen, 2004 [25]
(Telephoning people aged 16–66 years
who had not responded to initial invitation by 2 weeks.
Comparator was no call. Calls were made by research team.
People were being recruited to a return to work trial for people
on sick leave for > 7 weeks).
498 31/256 11/242 4.5% 8% (3%–12%)
Wong, 2013 [26]
(Telephoning people aged 50–70 years who
had not responded to initial invitation by 4 weeks.
Comparator was no call. Calls were made by research nurses.
People were being recruited to a colorectal cancer screening trial).
952 59/480 35/472 7.4% 5% (1%–9%)
Cumulative results
(Nystuen +Wong)
1450 90/736 46/714 6.0% (mean) 6% (3%–9%)
The GRADE rating of the certainty in the evidence is high
1. Both trials are scored as low risk of bias on the Cochrane Risk of bias tool
2. The results are consistent
3. The outcome was direct
4. The results are not imprecise; the confidence intervals are not too large and wholly on the side of benefit
5. There are too few trials for an assessment of publication bias and we have assumed that there is none
NOTE: the evidence for this intervention comes entirely from trials with low (< 10%) underlying recruitment. When applied to trials with higher recruitment we
would downgrade the GRADE assessment because of Indirectness to moderate
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when deciding whether they want to use the interven-
tion in their own trial based on the current evidence. A
trialist looking for a 10% or better increase in recruit-
ment would probably decide that telephone reminders
are not worth the effort, especially if underlying recruit-
ment is not expected to be low. While a trialist expect-
ing very low underlying recruitment might decide that
any increase, even a small one, is worth having and plan
their resource use accordingly. In both circumstances,
the trialists would need to speculate on the balance of
benefit to disadvantage.
Example 2: monetary incentives to increase
response rates to trial questionnaires
Background
The 2013 Cochrane Review of interventions to improve
trial retention [2] found that monetary incentives seem
to improve response rates to trial questionnaires. A trial
team that includes people with lived experience of the
illness or condition targeted is likely to consider infor-
mation about the following essential when deciding
whether a further evaluation of financial incentives
should form part of their retention strategy:
i. effect on questionnaire response rate (retention)
ii. cost
iii. participant irritation at receiving a small, unsolicited
gift
Applying the five criteria
Table 3 summarises the results of the three monetary in-
centives trials and the overall estimate of effect.
Applying the criteria in Table 1:
1. GRADE. Data are available for questionnaire
response rates only (three trials, n = 3166). The
overall GRADE certainty in the evidence is
moderate. Criterion met (the GRADE certainty in
the evidence for all essential outcomes is lower than
‘high’).
2. Cumulative evidence. Data are available for
questionnaire response rates only. There are only
three trials and it seems too early to claim that the
cumulative meta-analysis has converged. Criterion
met (the effect estimate for each essential outcome
has not converged).
3. Context. The PICOT for the available evidence is:
 P – Two trials were done in the UK, one in
2002–2003 and the other in 2007–2008. The
first involved women who had had a baby.
The second UK study involved people aged >
18 years who attended emergency
departments with a whiplash injury of < 6 six
Fig. 1 Summary of the cumulative evidence for the effect of telephone reminders on trial recruitment. The dotted lines represent decision
thresholds of 0%, 5%, 10% and 15% that trialists can consider when deciding whether to use the intervention in their own trial
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weeks’ duration. A third trial was done in the
US in 2001 and involved smokers who
wanted to stop.
 I – The host trial intervention in the 2002–2003
UK study was an antibiotic, while in the 2007–2008
UK study the host trial intervention was a book of
advice about whiplash, with that advice being
reinforced depending on the persistence of
symptoms. The host trial intervention in the US
study was a community-based program of public
education, advice from healthcare providers, work-
site initiatives and smoking cessation resources.
 C – The host trial comparator in the 2002/3 UK
study was placebo and usual whiplash advice in
the 2007/8 UK study. The host trial comparator
in the 2001 study was no community-based
smoking cessation program.
 O – All studies measured retention to the host
trial. All three host trials had underlying
retention < 50%.
 T – The most recent of these studies was done
in 2007–2008 so inflation and other societal
changes may affect the attractiveness of the
amounts paid.
Considering the above, leads to Criterion partially
met (a new evaluation is likely to contain several
elements in the PICOT that are importantly different to
those in the three existing evaluations).
1. Balance – participants. There is modest financial
benefit to participants who receive the incentive.
The potential disadvantage of a participant feeling
coerced to provide questionnaire data seems low
given the size of financial incentive being offered in
these trials (US$10 or less) although whether these
small amounts are perceived as insulting or
irritating is unclear. Criterion partially met (the
balance of benefit and disadvantage to participants
in the new host trial and/or SWAT is not clear).
2. Balance – host trial. The benefit to the host trial is a
modest increase in response rates. The potential
disadvantage to the host trial of the costs of
providing the incentives is quantifiable. Workload
may be increased (e.g. someone has to manage
vouchers or other incentives) but this is unlikely to
be much larger than the work needed anyway to send
out questionnaires. Criterion not met (the balance of
benefit and disadvantage to those running the host
trial is clear and can be estimated for each trial
depending on the size of the incentive).
Considering the responses across all five criteria leads
us to conclude that further evaluation of financial
Table 3 The cumulative effect estimates for the three monetary incentives compared to no incentive studies included in the
Cochrane retention interventions review [2]
Total number
of participants
Intervention (n
recruited/N invited)
Control (n
recruited/N
invited)
Baseline (control)
recruitment rate
Effect
estimate
(95% CI)
Bauer, 2004 [27]
(Sending $10 or $2 with invitations to return DNA
sample (in mouthwash). Comparator was no money.
People responding were a subgroup of a smoking
cessation trial population).
300 77/200 34/100 34% 5% (−7% to 16%)
Kenyon, 2005 [28]
(Sending £5 voucher with invitations to return trial
follow-up questionnaire. Comparator was no money.
People responding were taking part in a trial to improve
neonatal outcomes).
722 156/369 108/353 31% 12% (5%–19%)
Gates, 2009 [29]
(Sending £5 voucher with invitations to return trial
follow-up questionnaire. Comparator was no money.
People responding were taking part in a trial to improve
neck injury outcomes).
2144 560/1070 493/1074 46% 6% (2%–11%)
Cumulative results
(Bauer + Kenyon + Gates)
3166 793/1639 635/1527 37% (mean) 8% (4%–11%)
The GRADE rating of the certainty in the evidence is moderate
1. Only one of the three trials is scored as low risk of bias on the Cochrane Risk of bias tool; one was uncertain, the other high risk of bias. We considered this a
serious limitation and downgraded 1 level
2. The results have some inconsistency in confidence intervals but not the direction of effect and on balance we decided not to downgrade
3. The outcome was direct
4. The results showed signs of imprecision but just for the smallest trial; the confidence intervals of the two larger trials are not too large and wholly on the side
of benefit. We did not downgrade
5. There are too few trials for an assessment of publication bias and we have assumed that there is none
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incentives is needed with priority given to evaluation in
trials expected to have underlying retention > 50%. The
views of people with lived experience of the conditions
targeted by host trials on receiving small, unsolicited
payments should be sought in future evaluations. Future
randomised evaluations should ensure that they are
assessed as at low risk of bias on the Cochrane Risk of
Bias tool [30] to move the GRADE assessment from
moderate to high.
Figure 2 shows how Trial Forge might summarise the
evidence with regard to monetary incentives for retention.
Discussion
Trial Forge is an initiative to strengthen the evidence
base for trial process decision-making, as one step to-
wards improving the effectiveness and efficiency of those
processes. SWATs are an important way of contributing
to that evidence base. However, in order to minimise re-
search waste arising from the SWATs themselves, their
designers need to be confident that enough evidence is
not already available from evaluations of a given inter-
vention to support good, evidence-informed decisions.
The five criteria shown in Table 1 provide a basis to
determine whether this is the case. Although this ap-
proach requires judgement, it provides a transparent
mechanism for deciding whether the GRADE assessment
of the certainty of the evidence, cumulative meta-
analysis, host trial contexts and balance of benefit and
disadvantage suggest that there is merit in evaluating the
intervention in more SWATs, or whether there is
already enough information to support evidence-
informed decision-making about the relevant trial
process. It also provides a way to frame and track discus-
sion between researchers on particular SWATs—recog-
nising that there will be disagreements but providing
clarity about these disagreements and subsequent
decision-making. Moreover, using this approach will
help to identify and prioritise SWATs where there is
existing but insufficient evidence and the type of host
trials that should be targeted to build the evidence base.
The criteria can also be used with decision thresholds
(e.g. benefits of 5%, 10%, 15% or more) to help people
decide whether they want to use the intervention based
on the existing evidence even if more evaluations are
needed.
We will pilot this technique and the five criteria for
those SWATs promoted through Trial Forge, making
clear statements for these evaluations akin to those given
above for the two examples. We expect that the tech-
nique will be refined and improved over time but, for
now, the approach provides a starting foundation. Some
areas that need work are mentioned below as limitations.
Fig. 2 Summary of the cumulative evidence for the effect of monetary incentives on trial retention. The dotted lines represent decision
thresholds of 0%, 5%, 10% and 15% that trialists can consider when deciding whether to use the intervention in their own trial
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The criteria might also be linked to the SWAT reposi-
tory (http://bit.ly/20ZqazA), to improve the accessibility
of SWAT results and ongoing SWAT evaluations. Show-
ing that the criteria support a further evaluation of an
intervention in a SWAT is also likely to be helpful to
those deciding about applications for funding of new
SWAT evaluations by providing reassurance about the
need for the work and its contribution to the body of
evidence.
There are some limitations. The sparseness of the trial
process evidence base means that it is currently unlikely
that applying the five criteria to any body of evidence
will lead to a decision not to start another evaluation.
We did want to include an example that would have
shown the criteria concluding that more evaluations
were unnecessary but the current paucity of research
into trial processes means that we could not find one. In
addition, the criteria have been developed by a group of
SWAT enthusiasts who are based mainly in the UK or
Ireland. Others may prefer different criteria and we hope
that this paper will stimulate discussion and lead to re-
finements as these and other criteria are applied. An-
other limitation is the potential for publication bias.
Anecdotally, we know that some SWATs are done but
not published, which means our evidence summaries
and judgements could suffer from publication bias. As
others have noted [31], it is extremely difficult to be cer-
tain that publication bias is absent but by including
GRADE, our criteria do include an explicit consideration
of the potential for publication bias. Applying our cri-
teria systematically across many SWAT interventions
will also need resources. Finding these might be a chal-
lenge but our hope is that by demonstrating the value of
the criteria in reducing research waste by highlighting
when further evaluations of a SWAT are (or are not)
needed will make it easier to secure resources in the
future.
The most troubling limitation is likely to relate to the
third criterion and the issue of context, which is no less
thorny in SWATs than it is in the host trials in which they
sit. We suggest a PICOT framework to consider context-
ual factors and there may be a need for additional factors
to be considered. For example, our criteria do not expli-
citly dwell on the behavioural theory or mechanism of ac-
tion behind a SWAT intervention and whether these
theories and mechanisms still apply outside the context in
which the intervention was developed. Our criteria may
need to change, especially as bodies of SWAT evidence
get larger. We welcome suggestions for the key variables
needed by trial teams and others to make judgements
about context, which can then be considered for inclusion
in the Context criterion.
Finally, in a spirt of pragmatism about evidence gener-
ation, we recognise that less than perfect might be good
enough and certainly better than no evidence at all. This
may mean that the most efficient way of approaching
the limited time and money available for evidence gener-
ation about trial processes may be to focus on whether
something clears a threshold that makes it worth doing,
rather than having a precise estimate of its effect. There
would be little to gain from pursuing perfection if it will
not change decisions. If we want to avoid wasting re-
sources and participant goodwill, we need to think care-
fully about when enough is enough.
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